The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Why place a trial in a country where your chance of getting the new medicine to citizens is only 49%?' says AZ's Angela ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AstraZeneca's medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition. Shares slumped and were on track for the worst day ...

Oncology specialist AstraZeneca PLC (AZN) just released its results for Q2 2026 and H1 2026. They aren't bad at all, especially on the core EPS front. But the regional revenue breakup poses concerns ...

AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug candidates with potential advantages over ...

LONDON, July 24 (Reuters) - ⁠AstraZeneca's ⁠long-time CEO Pascal Soriot has rarely put a ⁠foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above ...

When I last wrote about the oncology-focused company, AstraZeneca PLC (AZN) in November, a Buy rating appeared contrarian. Following a fraud investigation in China, its price saw a sharp fall. And ...

AstraZeneca Plc is increasingly looking to the United States for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drug maker’s share price. Chief ...